- Genetic Alliance UK /
- Westminster APPG
What is an All Party Parliamentary Group?
All Party Parliamentary Groups (APPGs) are informal, cross-party interest groups of MPs and Peers interested in a particular issue. APPGs do not have any power to make laws and are not funded by Parliament. There is a great number of APPGs, covering many and diverse fields such as health, education, transport, defence, finance, the media and sports.
About the APPG on Rare, Genetic and Undiagnosed Conditions
The APPG on Rare, Genetic and Undiagnosed Conditions held its Annual General Meeting in February 2019. The aims of the group, agreed by members, are to increase awareness of rare, genetic and undiagnosed conditions in parliament and help ensure that patients and families affected by these conditions have access to appropriate care and support.
The APPG provides a useful forum for parliamentarians to meet patients and families, who are often vital to converting complicated and abstract debates to the everyday reality of people’s lives. It also provides the opportunities for MPs to learn about the many similar issues facing patients and their families. The APPG helps to give patients affected by rare, genetic and undiagnosed conditions a voice in parliament.
There are over 40 members from across the House of Commons and House of Lords who are on the APPG. In January 2019, the APPG held its Annual General Meeting and elected Catherine West MP as Chairs, Rt Hon Dame Cheryl Gillan MP, Lord Turnberg, Rt Hon Baroness Neville-Jones and Lord Patel as Vice-Chairs and Alex Sobel MP and Rt Hon Norman Lamb MP as officers.
What has the APPG worked on so far?
Rare Disease Day
On 27 February 2019, the APPG held its Annual General Meeting at the 2019 Rare Disease Day reception.
On 23 January 2019, the APPG held on social care and rare conditions. The hearing provided attendees with the opportunity to hear real life experiences of those using and working within the social care system.
Access to rare disease medicines in England
On 3 December 2018, the APPG held a third hearing on access to rare disease medicines in England. The hearing provided attendees with the opportunity to hear from individuals and organisations with experience of working in the field of rare diseases. An update was also provided on Genetic Alliance UK’s Resetting the Model project.
- Minutes from the hearing on Monday 3 December
- Nick Medhurst, Head of Policy and Public Affairs at the Cystic Fibrosis Trust, writes about the ongoing negotiations for access to new cystic fibrosis treatments
European Reference Networks
On Monday 9 July the All Party Parliamentary Group (APPG) on Rare, Genetic and Undiagnosed Conditions held a meeting on the effect of Brexit on European Reference Networks (ERNs). The APPG ran this event following guidance from Genetic Alliance UK.
Report on living with a rare condition: the effect on mental health
On Wednesday 9 May the Rare Disease UK campaign launched their report on the mental health impact of living with a rare disease. This work evolved from an inquiry conducted by the All Party Parliamentary Group (APPG) on Rare, Genetic and Undiagnosed Conditions, which identified mental health as a key issue facing rare disease patients and carers.
Access to rare disease medicines in England
On 11 October 2017, the APPG held a second hearing on access to rare disease medicines in England. This was an opportunity to hear from industry experts about their experiences of the current systems under NICE and NHS England in assessing rare disease medicines. There was also the opportunity to hear from patient organisations about the difficulties they have faced in trying to access medicines.
- The full briefing of the hearing
- Minutes from the hearing on Wednesday 11 October
- Our summary of the hearing
Report on the implementation of the UK Strategy for Rare Diseases in England
The UK Strategy for Rare Diseases was published in November 2013 and sets out 51 commitments that, if implemented, will provide those living with rare conditions with the highest possible quality of evidence-based care and treatment, regardless of where they live in the UK. The four countries of the UK have until 2020 to implement the 51 commitments outlined in the Strategy. In order to help put these into action, each country agreed to develop its own implementation plan by February 2014. The departments of health in Scotland, Wales and Northern Ireland have all published country specific plans that reflect their respective health service structures and priorities. The Department of Health in England has not developed or coordinated a plan.
In October 2016, the APPG launched an inquiry into the implementation of the Strategy in England. On Rare Disease Day 2017, 28 February 2017, it published Leaving No One Behind: Why England needs an implementation plan for the UK Strategy for Rare Diseases.
- The full report
- Sarah Stevens, a Public Health Consultant working at the National Congenital Anomalies and Rare Disease Registration Service, spoke at the report’s launch event in Parliament
On March 28 2017, in response to the findings and recommendations of the report, the Minister of State for Health, Philip Dunne MP, announced that NHS England and the Department of Health will develop an implementation plan for the commitments outlined in the Strategy.
Hearings with the Department of Health and its arm’s length bodies
As part of its inquiry into the implementation of the Strategy in England, in November 2016, the APPG hosted a series of hearings with patient representatives, the Department of Health and its arm’s length bodies:
- Minutes from the hearing on Tuesday 15 November
- Our summary of the hearing on Tuesday 15 November
- Minutes from the hearing on Monday 7 November
- Our summary of the hearing on Monday 7 November
- Minutes from the hearing on Tuesday 1 November
- Our summary of the hearing on Tuesday 1 November
- Overview of all three hearings
Access to medicines
On 11 October 2016, the APPG held a hearing on access to medicines. This was an opportunity to hear from rare disease patients, patient representatives, clinicians and industry experts to understand the issues they face in accessing medicines for patients affect by rare conditions within the current system in England.
- The full briefing for the hearing
- Minutes from the hearing
- Our summary of the hearing
- Jayne Spink, CEO of the Tuberous Sclerosis Association, wrote about the impact of delays in patients’ access to treatments
In May 2016, the APPG launched its first report exploring the experience of families who have received a diagnosis via genome sequencing. This was a timely report given that genome sequencing is becoming quicker and cheaper with every passing week; receiving a diagnosis through sequencing is now a reality for families. The report was launched at an event in parliament, and the then minister in charge of rare diseases, George Freeman MP, received the report.
- The full report: Undiagnosed genetic conditions and the impact of genome sequencing
- Sarah Oakes, the parent of a child with an undiagnosed condition, spoke at the APPG’s launch event in Westminster
- Our summary of the Westminster event
If you have any questions, or would like some further assistance, please contact Sarah Gilbert at [email protected] or call 020 7 831 0883.
This is not an official website of the House of Commons or the House of Lords. It has not been approved by either House or its committees. All-Party Parliamentary Groups are informal groups of Members of both Houses with a common interest in particular issues. The views expressed in these webpages are those of the group.